Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Molecular Diagnosis & Therapy
Erschienen in: Molecular Diagnosis & Therapy 5/2015

01.10.2015 | Review Article

Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis

verfasst von: François Curtin, Hervé Perron, Raphael Faucard, Hervé Porchet, Alois B. Lang

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Human endogenous retroviruses (HERV) represent about 8 % of the human genome. Some of these genetic elements are expressed in pathological circumstances. A HERV protein, the multiple sclerosis–associated retrovirus (MSRV) envelope protein (MSRV-Env), is expressed in the blood and active brain lesions of multiple sclerosis (MS) patients. It possesses pro-inflammatory and myelinotoxic properties. The patterns of expression and pathogenic properties of MSRV-Env make it a relevant drug target for MS therapeutics—in particular for preventing neurodegeneration, a key component of progressive forms of MS. An immunoglobulin G4 monoclonal antibody (mAb), called GNbAC1, has been developed to neutralize this pathogenic target. After showing neutralizing effects in vitro and in mouse models of MS, GNbAC1 is now in phase II clinical development. MSRV-related biomarkers such as MSRV-Env and MSRV polymerase (MSRV-Pol) gene transcripts are overexpressed in the blood and cerebrospinal fluid of patients with MS. These biomarkers may have prognostic value for long-term MS evolution, and their transcription levels in blood decline during treatments with GNbAC1, which has also been reported in patients administered reference MS drugs such as natalizumab or interferon-β. GNbAC1 as a new MSRV-Env-antagonist mAb could be a specific and causal treatment for MS, with a particular application for progressive forms of the disease. For possible use in companion diagnostic tests, MSRV-associated biomarkers could open the door to a personalized therapeutic approach for MS.
Literatur
1.
McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913–9.CrossRefPubMed
2.
Sadiq SA. Multiple sclerosis. In: Rowland LP, editor. Merrit’s neurology. Philadelphia: Lippincott, William & Wilkins; 2005. p. 941–59.
3.
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770–82.CrossRefPubMed
4.
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, Milanov I. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13:700–22.CrossRefPubMed
5.
Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210–8.CrossRefPubMed
6.
7.
Curtin F, Hartung HP. Novel therapeutic options for multiple sclerosis. Expert Rev Clin Pharmacol. 2014;7:91–104.CrossRefPubMed
8.
Kremer D, Küry P, Dutta R. Promoting remyelination in multiple sclerosis: current drugs and future prospects. Mult Scler. 2015;21:541–9.CrossRefPubMed
9.
Voisset C, Blancher A, Perron H, Mandrand B, Mallet F, Paranhos-Baccala G. Phylogeny of a novel family of human endogenous retrovirus sequences, HERV-W, in humans and other primates. AIDS Res Hum Retroviruses. 1999;15:1529–33.CrossRefPubMed
10.
Belshaw R, Pereira V, Katzourakis A, Talbot G, Paces J, Burt A, Tristem M. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci USA. 2004;101:4894–9.PubMedCentralCrossRefPubMed
11.
12.
13.
Feschotte C, Gilbert C. Endogenous viruses: insights into viral evolution and impact on host biology. Nat Rev Genet. 2012;13:283–96.CrossRefPubMed
14.
Perron H, Jouvin-Marche E, Michel M, Ounanian-Paraz A, Camelo S, Dumon A, Jolivet-Reynaud C, Marcel F, Souillet Y, Borel E, Gebuhrer L, Santoro L, Marcel S, Seigneurin JM, Marche PN, Lafon M. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology. 2001;287:321–32.CrossRefPubMed
15.
Rolland A, Jouvin-Marche E, Saresella M, Ferrante P, Cavaretta R, Créange A, Marche P, Perron H. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis. J Neuroimmunol. 2005;160:195–203.CrossRefPubMed
16.
Perron H, Dougier-Reynaud HL, Lomparski C, Popa I, Firouzi R, Bertrand JB, Marusic S, Portoukalian J, Jouvin-Marche E, Villiers CL, Touraine JL, Marche PN. Human endogenous retrovirus protein activates innate immunity and promotes experimental allergic encephalomyelitis in mice. PLoS One. 2013;8:e80128.PubMedCentralCrossRefPubMed
17.
Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol. 2006;176:7636–44.CrossRefPubMed
18.
Saresella M, Rolland A, Marventano I, Cavarretta R, Caputo D, Marche P, Perron H, Clerici M. Multiple sclerosis–associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing–remitting multiple sclerosis. Mult Scler. 2009;15:443–7.CrossRefPubMed
19.
Firouzi R, Rolland A, Michel M, Jouvin-Marche E, Hauw JJ, Malcus-Vocanson C, Lazarini F, Gebuhrer L, Seigneurin JM, Touraine JL, Sanhadji K, Marche PN, Perron H. Multiple sclerosis–associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovirol. 2003;9:79–93.CrossRefPubMed
20.
Zhang J, Vandevyver C, Stinissen P, Mertens N, van den Berg-Loonen E, Raus J. Activation and clonal expansion of human myelin basic protein-reactive T cells by bacterial superantigens. J Autoimmun. 1995;8:615–32.CrossRefPubMed
21.
Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med. 2000;6:414–21.CrossRefPubMed
22.
23.
Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, Bassetto F, Doria A. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87:385–95.CrossRefPubMed
24.
Delogu LG, Deidda S, Delitala G, Manetti R. Infectious diseases and autoimmunity. J Infect Dev Ctries. 2011;5:679–87.PubMed
25.
Kremer D, Schichel T, Förster M, Tzekova N, Bernard C, van der Valk P, van Horssen J, Hartung HP, Perron H, Küry P. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol. 2013;74:721–32.CrossRefPubMed
26.
Reynolds R, Dawson M, Papadopoulos D, Polito A, Di Bello IC, Pham-Dinh D, Levine J. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol. 2002;31:523–36.CrossRefPubMed
27.
Polito A, Reynolds R. NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult central nervous system. J Anat. 2005;207:707–16.PubMedCentralCrossRefPubMed
28.
Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 2001;81:871–927.PubMed
29.
Brück W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis. J Neurol Sci. 2003;206:181–5.CrossRefPubMed
30.
Aharoni R, Herschkovitz A, Eilam R, Blumberg-Hazan M, Sela M, Bruck W, Arnon R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008;105:11358–63.PubMedCentralCrossRefPubMed
31.
32.
Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, Wallace JL, Deacon RM, Warren K, Power C. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci. 2004;7:1088–95.CrossRefPubMed
33.
Perron H, Lazarini F, Ruprecht K, Péchoux-Longin C, Seilhean D, Sazdovitch V, Créange A, Battail-Poirot N, Sibaï G, Santoro L, Jolivet M, Darlix JL, Rieckmann P, Arzberger T, Hauw JJ, Lassmann H. Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol. 2005;11:23–33.CrossRefPubMed
34.
Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieckmann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler. 2012;18:1721–36.PubMedCentralCrossRefPubMed
35.
Perron H, Van Horssen J. HERV-W Env protein is strongly upregulated in inflammatory multiple sclerosis lesions [poster no. P355]. ECTRIMS Congress; Copenhagen; 2013.
36.
Curtin F, Perron H, Kromminga A, Porchet H, Lang AB. Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. MAbs. 2015;7:265–75.CrossRefPubMed
37.
Kremer D, Förster M, Schichel T, Göttle P, Hartung HP, Perron H, Küry P. The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Mult Scler. 2015;21:1200–3.CrossRefPubMed
38.
Piaton G, Williams A, Seilhean D, Lubetzki C. Remyelination in multiple sclerosis. Prog Brain Res. 2009;175:453–64.CrossRefPubMed
39.
Bonora M, De Marchi E, Patergnani S, Suski JM, Celsi F, Bononi A, Giorgi C, Marchi S, Rimessi A, Duszyński J, Pozzan T, Wieckowski MR, Pinton P. Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process. Cell Death Differ. 2014;21:1198–208.PubMedCentralCrossRefPubMed
40.
Perron H, Bertrand JB, Faucard R, Bernard C, Von Horssen J, Firouzi R, Potoukalian J, Germi R, Garcia-Montojo M, Morand P, Marche P, Sanhadji K, Tourraine JL, Lang A, Curtin F. Novel humanized antibody therapy in multiple sclerosis targeting immunopathogenic protein from endogenous retroviral element while preserving hosts’ immune system [poster no. P470]. ECTRIMS Congress; Lyon; 2012.
41.
Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis–associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther. 2012;34:2268–78.CrossRefPubMed
42.
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Pasquier RD, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis–associated endogenous retrovirus in multiple sclerosis patients. Mult Scler. 2015;21:885–93.CrossRefPubMed
43.
Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Pasquier RD, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis–associated endogenous retrovirus in multiple sclerosis patients—a 12-month extension. J Neuroimmunol. 2015;285:68–70.CrossRefPubMed
44.
Zimmermann M, Sanderson N, Rasenack M, Lalive P, Curtin F, Lang A, Kappos L, Derfuss T. Immunomonitoring of a phase II study testing the monoclonal antibody GNbAC1 in multiple sclerosis patients [poster no. P1011]. ECTRIMS Congress; Copenhagen; 2013.
45.
Garson JA, Tuke PW, Giraud P, Paranhos-Baccala G, Perron H. Detection of virion-associated MSRV-RNA in serum of patients with multiple sclerosis. Lancet. 1998;351:33.CrossRefPubMed
46.
Arru G, Mameli G, Astone V, Serra C, Huang YM, Link H, Fainardi E, Castellazzi M, Granieri E, Fernandez M, Villoslada P, Fois ML, Sanna A, Rosati G, Dolei A, Sotgiu S. Multiple sclerosis and HERV-W/MSRV: a multicentric study. Int J Biomed Sci. 2007;3:292–7.PubMedCentralPubMed
47.
Dolei A, Serra C, Mameli G, Pugliatti M, Sechi G, Cirotto MC, Rosati G, Sotgiu S. Multiple sclerosis–associated retrovirus (MSRV) in Sardinian MS patients. Neurology. 2002;58:471–3.CrossRefPubMed
48.
Mameli G, Poddighe L, Astone V, Delogu G, Arru G, Sotgiu S, Serra C, Dolei A. Novel reliable real-time PCR for differential detection of MSRVenv and syncytin-1 in RNA and DNA from patients with multiple sclerosis. J Virol Methods. 2009;161:98–106.CrossRefPubMed
49.
Garcia-Montojo M, Dominguez-Mozo M, Arias-Leal A, Garcia-Martinez Á, De las Heras V, Casanova I, Faucard R, Gehin N, Madeira A, Arroyo R, Curtin F, Alvarez-Lafuente R, Perron H. The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity. PLoS One. 2013;8(1):e53623.PubMedCentralCrossRefPubMed
50.
Sotgiu S, Serra C, Mameli G, Pugliatti M, Rosati G, Arru G, Dolei A. Multiple sclerosis–associated retrovirus and MS prognosis: an observational study. Neurology. 2002;59:1071–3.CrossRefPubMed
51.
Sotgiu S, Arru G, Mameli G, Serra C, Pugliatti M, Rosati G, Dolei A. Multiple sclerosis–associated retrovirus in early multiple sclerosis: a six-year follow-up of a Sardinian cohort. Mult Scler. 2006;12:698–703.CrossRefPubMed
52.
Sotgiu S, Mameli G, Serra C, Zarbo IR, Arru G, Dolei A. Multiple sclerosis–associated retrovirus and progressive disability of multiple sclerosis. Mult Scler. 2010;16:1248–51.CrossRefPubMed
53.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology. 2005;64:1144–51.CrossRefPubMed
54.
Mameli G, Serra C, Astone V, Castellazzi M, Poddighe L, Fainardi E, Neri W, Granieri E, Dolei A. Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurovirol. 2008;14:73–7.CrossRefPubMed
55.
Arru G, Leoni S, Pugliatti M, Mei A, Serra C, Delogu LG, Manetti R, Dolei A, Sotgiu S, Mameli G. Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study. Mult Scler. 2014;20:174–82.CrossRefPubMed
56.
57.
58.
59.
Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40.CrossRefPubMed
60.
Perron H, Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol. 2010;39:51–61.CrossRefPubMed
61.
Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol. 2014;175:397–407.PubMedCentralCrossRefPubMed
62.
63.
Gotovac K, Hajnšek S, Pašić MB, Pivac N, Borovečki F. Personalized medicine in neurodegenerative diseases: how far away? Mol Diagn Ther. 2014;18:17–24.CrossRefPubMed
64.
Perron H, Hamdani N, Faucard R, Lajnef M, Jamain S, Daban-Huard C, Sarrazin S, LeGuen E, Houenou J, Delavest M, Moins-Teisserenc H, Bengoufa D, Yolken R, Madeira A, Garcia-Montojo M, Gehin N, Burgelin I, Ollagnier G, Bernard C, Dumaine A, Henrion A, Gombert A, Le Dudal K, Charron D, Krishnamoorthy R, Tamouza R, Leboyer M. Molecular characteristics of human endogenous retrovirus type-W in schizophrenia and bipolar disorder. Transl Psychiatry. 2012;2:e201.PubMedCentralCrossRefPubMed
65.
Faucard R, Madeira A, Panaite PA, Lesage C, Gehin N, Burgelin I, Curtin F, Lang AB, Steck A, Perron H, Kuntzer T, Créange A. Multiple sclerosis associated retrovirus (MSRV) envelope expression in peripheral blood mononuclear cells is associated with CIDP [poster]. Saint-Malo: Peripheral Nerve Society Meeting; 2013.
66.
Perl A, Nagy G, Koncz A, Gergely P, Fernandez D, Doherty E, Telarico T, Bonilla E, Phillips PE. Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity. 2008;41:287–97.CrossRefPubMed
67.
Nelson PN, Roden D, Nevill A, Freimanis GL, Trela M, Ejtehadi HD, Bowman S, Axford J, Veitch AM, Tugnet N, Rylance PB. Rheumatoid arthritis is associated with IgG antibodies to human endogenous retrovirus gag matrix: a potential pathogenic mechanism of disease? J Rheumatol. 2014;41:1952–60.CrossRefPubMed
68.
Tugnet N, Rylance P, Roden D, Trela M, Nelson P. Human endogenous retroviruses (HERVs) and autoimmune rheumatic disease: is there a link? Open Rheumatol J. 2013;7:13–21.PubMedCentralPubMed
69.
Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69:141–51.PubMedCentralCrossRefPubMed
70.
Sander DM, Szabo S, Gallaher WR, Deas JE, Thompson JJ, Cao Y, Luo-Zhang H, Liu LG, Colmegna I, Koehler J, Espinoza LR, Alexander SS, Hart DJ, Tom DM, Fermin CD, Jaspan JJ, Kulakosky PC, Tenenbaum SA, Wilson RB, Garry RF. Involvement of human intracisternal A-type retroviral particles in autoimmunity. Microsc Res Tech. 2005;68:222–34.CrossRefPubMed
Metadaten
Titel
Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis
verfasst von
François Curtin
Hervé Perron
Raphael Faucard
Hervé Porchet
Alois B. Lang
Publikationsdatum
01.10.2015
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 5/2015
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-015-0166-z

Weitere Artikel der Ausgabe 5/2015

Molecular Diagnosis & Therapy 5/2015 Zur Ausgabe

Original Research Article

High Frequency and Poor Prognosis of Late Childhood BCR-ABL-Positive and MLL-AF4-Positive ALL Define the Need for Advanced Molecular Diagnostics and Improved Therapeutic Strategies in Pediatric B-ALL in Pakistan

Original Research Article

Association of MDR1 Gene (C3435T) Polymorphism and Gene Expression Profiling in Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Original Research Article

Altered microRNA Expression Profile in Synovial Fluid from Patients with Knee Osteoarthritis with Treatment of Hyaluronic Acid

Short Communication

Frequency of Transmitted Drug Resistance Mutations Among Treatment-Naïve HIV-1-Infected Individuals at a Tertiary Care Centre in South India

Original Research Article

Evaluation of miR-27a, miR-181a, and miR-570 Genetic Variants with Gallbladder Cancer Susceptibility and Treatment Outcome in a North Indian Population

Original Research Article

Novel T-Cell Assays for the Discrimination of Active and Latent Tuberculosis Infection: The Diagnostic Value of PPE Family

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise